CSL breaks ground on $1.5B Illinois immunoglobulin plant expansion

CSL is breaking ground on a $1.5 billion immunoglobulin manufacturing plant in Kankakee, Illinois to produce plasma-derived therapies. The expansion represents part of the company's broader $3 billion investment strategy to strengthen its U.S. biopharmaceutical manufacturing capacity.

The Kanakee project builds on the biopharma company’s efforts to increase its U.S. footprint, where it has already spent more than $3 billion, and will focus on producing plasma-derived therapies.

This story was originally published by Construction Dive.